Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) EBT Margin (2016 - 2024)

Historic EBT Margin for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to 24.29%.

  • Capricor Therapeutics' EBT Margin fell 174400.0% to 24.29% in Q4 2024 from the same period last year, while for Sep 2025 it was 242.77%, marking a year-over-year decrease of 1220900.0%. This contributed to the annual value of 100.9% for FY2024, which is 121400.0% down from last year.
  • Per Capricor Therapeutics' latest filing, its EBT Margin stood at 24.29% for Q4 2024, which was down 174400.0% from 555.2% recorded in Q3 2024.
  • In the past 5 years, Capricor Therapeutics' EBT Margin ranged from a high of 6.86% in Q4 2023 and a low of 23187.59% during Q3 2020
  • Moreover, its 5-year median value for EBT Margin was 477.75% (2022), whereas its average is 3521.29%.
  • In the last 5 years, Capricor Therapeutics' EBT Margin crashed by -220567500bps in 2020 and then skyrocketed by 45047700bps in 2021.
  • Over the past 5 years, Capricor Therapeutics' EBT Margin (Quarter) stood at 7224.51% in 2020, then soared by 66bps to 2482.54% in 2021, then surged by 68bps to 800.77% in 2022, then skyrocketed by 99bps to 6.86% in 2023, then tumbled by -254bps to 24.29% in 2024.
  • Its EBT Margin was 24.29% in Q4 2024, compared to 555.2% in Q3 2024 and 276.97% in Q2 2024.